ftInvstr
BLISSGVS · Healthcare ₹671.3 +5.38% Mkt Cap ₹7102 Cr

BLISSGVS

Healthcare Drug Manufacturers - Specialty & Generic
₹671.3
+5.38% today · 30d +36.44%
as of 2026-09-04
Price · Daily Candles
“Bliss GVS Surges 210% in a Year as Profit Doubles, While FIIs Trim Holdings.”
Bliss GVS Pharma has seen a remarkable 210.99% price return over the past year, driven by strong quarterly performance with net profit jumping 122.18% YoY to ₹37 Cr. Despite this, FIIs reduced their stake by 4.09% QoQ, and DIIs by 0.74% QoQ, while the public's share grew by 4.83% QoQ.
BULL CASE
+Net profit soared 122.18% YoY to ₹37 Cr in Q4 2026, alongside a 29.8% YoY revenue increase to ₹257 Cr.
+The company's stock delivered a 210.99% return over the past year, with a 3-month return of 87.34%.
+Annual net profit grew 49.27% YoY to ₹135 Cr in FY26, with a 3-year CAGR of 23.88%.
+Profitability is high with an OPM of 20.73% in Q4 and a composite business score indicating 'STRONG' performance and 'HIGH' profitability.
BEAR CASE
FIIs significantly decreased their stake by 4.09% QoQ, and DIIs reduced theirs by 0.74% QoQ.
The stock is trading 12.29% below its 52-week high of ₹553.0 after a recent -5.26% daily dip.
ML model predicts weak Free Cash Flow growth, with ranks for FCF growth ranging from 0.0 to 0.267, indicating a 'weak' outlook.
The PE ratio of 42.01 is higher than Cipla's 29.68 and Zydus Life's 22.27, suggesting a potentially higher valuation.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹286 Cr
+37.65% YoY
NET PROFIT
₹51 Cr
+15.8% YoY
OPM
29.14%
-2.47pp YoY
EPS
₹4.73
PE 42.01
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-0.2%, h2=-1.7%, h3=+0.6% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Bliss GVS, with a PE of 42.01 and ROCE of 17.0%, trades at a higher valuation than peers like Cipla (PE 29.68, ROCE 25.09%) and Zydus Life (PE 22.27, ROCE 25.71%), despite a lower ROCE.
PEERPEROCE %
BLISSGVS42.0117.0
SUNPHARMA42.3422.46
DIVISLAB77.6121.47
CIPLA29.6825.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
76
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation FAIR 40
Growth STRONG 74
Profitability HIGH 85
Technicals NEUTRAL 68
Risk LOW 90
Key Stats
TTM PE
42.01
P/B
4.29
52W HIGH
₹671.3
OFF HIGH
0.0%
DIV YIELD
0.4%
MKT CAP
₹7102 Cr
◉ Active Signals
MACDBullish9.4688
RSI(14)Bearish77.99
Near 52W HighBullish0.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold BLISSGVS and at what entry.

Sign up freeSign in